Forbes Reduces Net Worth of Theranos CEO Elizabeth Holmes from $4.5 Billion to Zero

eliza10-e1443575290391

The woman who was once considered the world’s youngest self-made female billionaire now has a networth of zero.

Elizabeth Holmes, 31, is the chief executive of her health technology company Theranos Inc. which promised to make blood tests easier and more affordable for patients. Holmes, a Stanford dropout, reportedly owns 50% of Theranos, which was valued at $9 billion.

eliza4-e1443575297394

After founding Theranos at the age of 19, she worked tirelessly to follow through on her guarantee of delivering more convenient methods of diagnosing patients using a single drop of blood. Today, her company is currently under investigation by several federal and state agencies including the U.S. Securities and Exchange Commission, state health departments in Arizona and Pennsylvania, the Centers for Medicare and Medicaid and the U.S. Food and Drug Administration.

eliza7-e1443575269227

In a suit filed last week, Theranos was accused of “massive failures” that misrepresented the accuracy and quality of its blood tests. The misrepresentation put patients’ health and well-being at risk, the suit stated.

Forbes reported that private investors, including the likes of Larry Ellison, former CEO of Oracle, bought stakes in the company that indicated a $9 billion valuation. However, the magazine noted $800 million was a more realistic estimate. Additional findings reveal that the company’s annual revenues are below $100 million.

Forbes concluded:

“At such a low valuation Holmes’ stake is essentially worth nothing.”

eliza11-e1443575334296

Forbes explained that investors in Theranos own preferred shares while Holmes, who has a 50% stake in Theranos, has common stock. In the event of a liquidation, participating preferred shares “take precedence to common stock.” If Theranos were to liquidate, investors “would get their money back and more before Holmes gets a cent.”

Holmes is expected to present findings based on Theranos’ data at the annual meeting of the AACC, or American Association for Clinical Chemistry, in August.

Related Posts

Support our Journalism with a Contribution

Many people might not know this, but despite our large and loyal following which we are immensely grateful for, NextShark is still a small bootstrapped startup that runs on no outside funding or loans.

Everything you see today is built on the backs of warriors who have sacrificed opportunities to help give Asians all over the world a bigger voice.

However, we still face many trials and tribulations in our industry, from figuring out the most sustainable business model for independent media companies to facing the current COVID-19 pandemic decimating advertising revenues across the board.

We hope you consider making a contribution so we can continue to provide you with quality content that informs, educates and inspires the Asian community. Even a $1 contribution goes a long way. Thank you for everyone’s support. We love you all and can’t appreciate you guys enough.

NextShark is a leading source covering Asian American News and Asian News including business, culture, entertainment, politics, tech and lifestyle.

For advertising and inquiries: info@nextshark.com